NGR peptide Trifluoroacetate

C22H37F3N10O10S2

H2O : >= 100 mg/mL (138.37 mM)

Metabolic Enzyme/Protease

NGR peptide Trifluoroacetate containing the asparagine-glycine-arginine (NGR) motif is recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature. IC50 & Target: CD13/aminopeptidase N (APN) receptor^[1] In Vitro: NGR peptide can selectively bind to APN/CD13 either immune-captured or expressed on the surface of cells, the receptor of the tumor-homing NGR peptide was suspected to be APN/CD13. The NGR peptide is reported to have the greatest tumor selectivity. An anti-cancer drug Doxorubicin (DOX) coupled to an NGR peptide displays enhanced anti-tumor effects with even lower toxicity than the free drug itself^[2]. In Vivo: NGR peptide imaging in vivo not only provides more insight into NGR�s targeting process, including bio-distribution and pharmacokinetics, but also reveals angiogenic activities related to tumor progression and malignancy^[2].